Takeda Pharmaceutical (NYSE:TAK) Shares Gap Up – What’s Next?

Takeda Pharmaceutical Co. (NYSE:TAK) shares gapped up before the market opened on Tuesday . The stock had previously closed at $17.38, but opened at $17.86. Takeda Pharmaceutical shares last traded at $18.1150, with a volume of 1,005,861 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TAK. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Up 1.7%

The firm’s 50-day moving average price is $16.70 and its 200 day moving average price is $17.17. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $58.84 billion, a price-to-earnings ratio of 54.01 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.30. The business had revenue of $7.50 billion for the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.5 EPS for the current fiscal year.

Insider Transactions at Takeda Pharmaceutical

In other news, General Counsel Natalie Anne Marie Furney sold 30,868 shares of Takeda Pharmaceutical stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $527,842.80. Following the transaction, the general counsel owned 204,298 shares in the company, valued at approximately $3,493,495.80. This trade represents a 13.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Nicola Deidre Petal Greenway sold 12,980 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total value of $235,067.80. Following the transaction, the insider directly owned 40,049 shares of the company’s stock, valued at $725,287.39. This trade represents a 24.48% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 457,080 shares of company stock worth $7,829,178. 0.04% of the stock is owned by insiders.

Institutional Investors Weigh In On Takeda Pharmaceutical

Hedge funds have recently made changes to their positions in the stock. Capital Research Global Investors lifted its stake in Takeda Pharmaceutical by 0.6% in the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after purchasing an additional 82,643 shares during the last quarter. UBS Group AG grew its stake in shares of Takeda Pharmaceutical by 46.4% during the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after buying an additional 1,869,323 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Takeda Pharmaceutical by 100.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after buying an additional 2,854,069 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after buying an additional 692,404 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after acquiring an additional 370,800 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.